With the move towards personalized care and value-based based models, Life Sciences companies and providers have strong incentives to identify populations at risk to improve outcomes, increase market access for drugs and devices, reduce total cost of treatment, and optimize care pathways and healthcare journeys.
Read More +For providers and life-science groups to drive personalized care and value-models they have to identify areas where population risk can be estimated and treatments can be personalized. In addition, providers have to minimize the negative outcomes over sub-populations (e.g. cardiac patients with negative outcomes).
Read More +
CapsicoHealth's Generative AI platform provides cloud-based tools for Life Sciences companies and healthcare groups to identify risk and trajectory when launching new drugs and devices and services by monitoring automatically multiple outcomes, competitor information, prescriptions, procedures and population diagnoses.
Read More +